The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients

• Status: Unknown status
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Gastroesophageal reflux disease(GERD) mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter. Proton pump inhibitors (PPI) can effectively block gastric acid secretion but the drug reactions and the degree of improvement in symptoms are sometimes unpredictable. The aim of this study is to investigate the association between the clinical efficacy of PPI in patients with GERD and the personal physical status by Ryodoraku and ANSWatch.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taichung Tzu Chi Hospital
• Treatments: Proton Pump Inhibitors; Rabeprazole

Criteria

Inclusion Criteria:

• male or female

• age of 20-75 years

• patients with GERD who have to receive PPIs for four weeks

Exclusion Criteria:

• Suffering from peptic ulcer, gallstones, cancer, and Barrett's esophagus

• previously underwent the esophagus, stomach or duodenum surgery

• Lactating women or pregnant women